Biosimilars | Specialty

The OncLive Biosimilars condition center page is a comprehensive resource for clinical news and expert insights on currently available and investigational biosimilars for reference drugs such as trastuzumab, rituximab, bevacizumab, and more. This page features news articles, interviews in written and video format, and podcasts that focus on updates with biosimilars and ongoing research with these types of agents.

Dr. Munster on Developing Biosimilars

January 2nd 2019

Pamela N. Munster, MD, professor, department of medicine (hematology/oncology), University of California, San Francisco (UCSF), director, early phase clinical trials unit, co-leader, Center for BRCA Research, leader, Experimental Therapeutics Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the developmental process for biosimilars in oncology.

Dr. Hurvitz on Importance of Biosimilars in HER2+ Breast Cancer

December 29th 2018

Sara A. Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses the importance of biosimilars in HER2-positive breast cancer.

Brufsky Anticipates Significant Cost Reductions With Biosimilars

December 20th 2018

Adam M. Brufsky, MD, PhD, discusses the impact of biosimilars in the field of oncology and outlined other strategies and steps that can be taken to mitigate cost when treating patients with breast cancer.

Biosimilar Filgrastim Would Lower Medicare Out-of-Pocket Expenses

December 19th 2018

Out-of-pocket expenditures are substantially less among Medicare beneficiaries with breast cancer undergoing chemotherapy who receive prophylaxis for febrile neutropenia with a filgrastim biosimilar as opposed to the reference product.

Dr. Brufsky on Ways to Mitigate Cost Before Biosimilars Reach US Market

December 18th 2018

Adam M. Brufsky, MD, PhD, professor of medicine, associate chief, Division of Hematology/Oncology, co-director, Comprehensive Breast Cancer Center, associate director, Clinical Investigation, University of Pittsburgh, discusses cost mitigation practices that can be implemented before more biosimilars reach the United States market.

Dr. Hamilton on the Addition of Biosimilars to Breast Oncology

December 17th 2018

Erika P. Hamilton, MD, director, Breast and Gynecologic Research Program, Sarah Cannon Research Institute, discusses the addition of biosimilars to breast oncology.

FDA Approves Trastuzumab Biosimilar for HER2+ Breast Cancer

December 17th 2018

The FDA has granted an approval to CT-P6, a trastuzumab biosimilar, for the treatment of patients with HER2-overexpressing breast cancer

Dr. De Censi Discusses Financial Benefit of Biosimilars

December 14th 2018

Andrea De Censi, MD, director of the medical oncology unit at the National Hospital E.O. Ospedali Galliera–SC Oncologia Medica in Genoa, Italy, discusses the financial benefit of biosimilars in oncology.

Trastuzumab Biosimilar CT-P6 Shows Comparable Efficacy at 2-Year Follow-up

December 14th 2018

CT-P6, a proposed biosimilar to trastuzumab, exhibited long-term disease-free survival and overall survival similar to the reference product in the treatment of patients with HER2-positive early breast cancer.

Markman Outlines Biosimilars and Cost-Effective Oncology Practices

December 14th 2018

Maurie Markman, MD, discusses the evolution of biosimilars and ongoing efforts to make treatments more affordable for patients with cancer.

Dr. Kolberg on Ensuring Confidence With Biosimilars in Oncology

December 12th 2018

Hans-Christian Kolberg, MD, head, Department of Obstetrics and Gynecology, Breast Cancer Center, and Gynecologic Cancer Center at Marienhospital Bottrop, Klinik für Gynäkologie und Geburtshilfe, Bottrop, Germany, discusses the importance of ensuring confidence with biosimilars in oncology.

Dr. Esteva on the Trastuzumab Biosimilar Candidate CT-P6 in HER2+ Breast Cancer

December 11th 2018

Francisco J. Esteva, MD, PhD, medical oncologist, New York University’s Perlmutter Cancer Center, discusses the efficacy and safety of the trastuzumab (Herceptin) biosimilar candidate CT-P6 in HER2-positive breast cancer.

Dr. Bardia on Potential Concerns With Biosimilars in Breast Cancer

December 11th 2018

Aditya Bardia, MD, MPH, director of Precision Medicine at the Center for Breast Cancer, Massachusetts General Hospital Cancer Center, Harvard Medical School, discusses potential concerns regarding the use of biosimilars in the breast cancer space.

Dr. Borgen Discusses the Global Impact of Biosimilars

December 8th 2018

Patrick I. Borgen, MD, chair, Department of Surgery, director, Breast Cancer, Maimonides Medical Center, discusses the potential global impact of biosimilars in oncology.

Dr. Pegram on the Manufacturing Process of Biosimilars

December 6th 2018

Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses the manufacturing process of biosimilars.

Dr. Brufsky Addresses Biosimilar Skepticism

December 5th 2018

Dr. Borgen Discusses the Equivalence of Biosimilars

December 4th 2018

Patrick I. Borgen, MD, chair, Department of Surgery, director, Breast Cancer, Maimonides Medical Center, discusses the equivalence of biosimilars in oncology.

Dr. Pegram on Projections of Cost Reductions With Biosimilars

December 4th 2018

Dr. Goy Discusses the Rituximab Biosimilar FDA Approval

November 29th 2018

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the FDA approval of the rituximab (Rituxan) biosimilar, CT-P10 (Truxima; rituximab-abbs), for the treatment of adult patients with CD20-positive, B-cell non-Hodgkin lymphoma as a single agent or in combination with chemotherapy.

FDA Approves First Biosimilar for Non-Hodgkin Lymphoma

November 28th 2018

The FDA has approved the first rituximab biosimilar, CT-P10, for the treatment of adult patients with CD20-positive, B-cell non-Hodgkin lymphoma as a single agent or in combination with chemotherapy.